Targeting cancer-associated glycans as a therapeutic strategy in leukemia
Unlike cytotoxic chemotherapy, cancer immunotherapy offers targeted therapies that exploit the effector mechanisms of the immune system to combat cancer. However, most therapeutic strategies have so far focused predominantly on the orchestration of the adaptive immune responses to anti-cancer immuno...
Main Author: | Ashraf Abdullah Saad |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | All Life |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/26895293.2022.2049901 |
Similar Items
-
Turning-off Signaling by Siglecs, Selectins and Galectins: Chemical Inhibition of Glycan-dependent Interactions in Cancer
by: Alejandro Javier Cagnoni, et al.
Published: (2016-05-01) -
Microglial Lectins in Health and Neurological Diseases
by: Jian Jing Siew, et al.
Published: (2018-05-01) -
Editorial: Lectins and Their Ligands in Shaping Immune Responses
by: Bernd Lepenies, et al.
Published: (2019-10-01) -
The Blessed Union of Glycobiology and Immunology: A Marriage That Worked
by: Jhenifer Santos dos Reis, et al.
Published: (2023-01-01) -
A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in Cancer
by: Lenneke A.M. Cornelissen, et al.
Published: (2016-05-01)